308 related articles for article (PubMed ID: 29633951)
21. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.
Vanden Berg RNW; Zilli T; Achard V; Dorff T; Abern M
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):702-711. PubMed ID: 37422523
[TBL] [Abstract][Full Text] [Related]
22. The current role of precision surgery in oligometastatic prostate cancer.
von Deimling M; Rajwa P; Tilki D; Heidenreich A; Pallauf M; Bianchi A; Yanagisawa T; Kawada T; Karakiewicz PI; Gontero P; Pradere B; Ploussard G; Rink M; Shariat SF
ESMO Open; 2022 Dec; 7(6):100597. PubMed ID: 36208497
[TBL] [Abstract][Full Text] [Related]
23. Metastasis-directed therapy in oligometastatic prostate cancer.
Miszczyk M; Soeterik T; Marra G; Matsukawa A; Shariat SF
Curr Opin Urol; 2024 May; 34(3):178-182. PubMed ID: 38426229
[TBL] [Abstract][Full Text] [Related]
24. CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.
Napieralska A; Miszczyk L; Stąpór-Fudzińska M
Technol Cancer Res Treat; 2016 Oct; 15(5):661-73. PubMed ID: 26208835
[TBL] [Abstract][Full Text] [Related]
25. [Stereotactic body radiation therapy for oligometastatic prostate cancer].
Bibault JE
Bull Cancer; 2018 Jan; 105(1):120-125. PubMed ID: 29191358
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic ablative radiation therapy in metastatic prostate cancer.
Bazyar S; Mannuel H; Tran PT
Curr Opin Oncol; 2024 May; 36(3):180-185. PubMed ID: 38362949
[TBL] [Abstract][Full Text] [Related]
27. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
28. [The role of radiotherapy to the primary tumor and metastases in patients with oligometastatic prostate cancer].
Le Roy T; Baron D; Vandendorpe B; Bataille B; Hannoun-Levi JM; Blanchard P; Lartigau E; Latorzeff I; Pasquier D
Cancer Radiother; 2021 Oct; 25(6-7):526-532. PubMed ID: 34400086
[TBL] [Abstract][Full Text] [Related]
29. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
[TBL] [Abstract][Full Text] [Related]
30. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.
Saluja R; Cheung P; Zukotynski K; Emmenegger U
Urol Oncol; 2016 May; 34(5):225-32. PubMed ID: 27008982
[TBL] [Abstract][Full Text] [Related]
31. Oligometastatic Prostate Cancer.
Navrátil J; Poprach A; Lakomý R; Kocák I; Vašina J; Krupa P; Vyzula R
Klin Onkol; 2019; 32(2):97-100. PubMed ID: 30995848
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.
Koo KC; Dasgupta P
Yonsei Med J; 2018 Jul; 59(5):567-579. PubMed ID: 29869454
[TBL] [Abstract][Full Text] [Related]
33. Oligometastatic prostate cancer: The game is afoot.
Lancia A; Zilli T; Achard V; Dirix P; Everaerts W; Gomez-Iturriaga A; Ingrosso G; Liefhooghe N; Miralbell R; Siva S; Van der Eecken K; Ost P
Cancer Treat Rev; 2019 Feb; 73():84-90. PubMed ID: 30684842
[TBL] [Abstract][Full Text] [Related]
34. Approach to Oligometastatic Prostate Cancer.
Bernard B; Gershman B; Karnes RJ; Sweeney CJ; Vapiwala N
Am Soc Clin Oncol Educ Book; 2016; 35():119-29. PubMed ID: 27249693
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.
De Bleser E; Tran PT; Ost P
Curr Opin Urol; 2017 Nov; 27(6):587-595. PubMed ID: 28816714
[TBL] [Abstract][Full Text] [Related]
36. Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.
Clement JM; Sweeney CJ
J Oncol Pract; 2017 Jan; 13(1):9-18. PubMed ID: 28045610
[TBL] [Abstract][Full Text] [Related]
37. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
Ost P; Jereczek-Fossa BA; As NV; Zilli T; Muacevic A; Olivier K; Henderson D; Casamassima F; Orecchia R; Surgo A; Brown L; Tree A; Miralbell R; De Meerleer G
Eur Urol; 2016 Jan; 69(1):9-12. PubMed ID: 26189689
[TBL] [Abstract][Full Text] [Related]
38. Treatment of the primary tumor in metastatic prostate cancer.
Yuan Y; Kishan AU; Nickols NG
World J Urol; 2019 Dec; 37(12):2597-2606. PubMed ID: 30456709
[TBL] [Abstract][Full Text] [Related]
39. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
40. [Oligorecurrent prostate cancer: current management and perspectives].
Loubersac T; Guimas V; Rio E; Libois V; Rigaud J; Supiot S
Bull Cancer; 2020 Jun; 107(5S):S35-S40. PubMed ID: 32620205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
